At A Glance
M3 MI's MARS Consumer Health Study empowers healthcare advertisers to create personalized campaigns by offering nuanced audience insights. By layering behavioral and engagement attributes, MARS enables accurate targeting, driving stronger engagement, improved ad recall, and measurable campaign outcomes across connected TV (CTV), social, and display channels.In our Ask the Expert Series, we interview leaders from our partner organizations who are helping lead their brands to new heights in AdTech. Today’s interview is with Dan Lynch a Senior Manager, Insights and Analysis at M3 MI, the company behind the MARS Consumer Health Study and MARS Audiences.
Audience impact across health vertical
Which healthcare advertisers see the greatest impact from MARS audiences? Could you share an example of how health marketers have successfully utilized your data to achieve specific campaign goals, such as patient engagement, awareness, or adherence?
We’re seeing a clear shift in healthcare advertising away from generic, one-size-fits-all campaigns. With MARS, advertisers from pharmaceuticals, over-the-counter (OTC), health insurance companies, and hospitals are seeing the greatest impact by defining highly specific patient and caregiver personas and using those insights to build personalized media plans and deliver unique messaging by segment. As a result, our partners are seeing stronger engagement, increased ad recall, and more effective outcomes because they’re speaking directly to what matters most to each audience.
Media agencies who utilize the MARS Consumer Health Study to build their strategic marketing plans are seeing a great impact by then taking those strategic targets and activating them. Those who are not activating those audiences are really missing out on bringing their strategy to consumer screens.
Building stronger health campaigns with advanced segmentation
What key health-related audience segments does MARS offer?
While other competitors may offer caregiver segments by condition, we go further by layering engagement levels, such as caregivers actively involved in medical decisions or those who regularly discuss care with physicians. Similarly, for patients, we don’t stop at identifying over 60 health conditions; we add behavioral dimensions like whether they’re proactive in managing their health or primarily doctor-led. These nuanced attributes allow advertisers to craft personalized campaigns that resonate on a much deeper level. We can also look at patients that are willing to pay more for an Rx not covered by their insurance, which has been a trend with GLP-1s.
How can health advertisers use these segments to craft more personalized and effective campaigns?
Advertisers can use MARS’ advanced segmentation to move beyond simple demographics or condition-based targeting by layering behavioral and engagement attributes for greater relevance and impact. With MARS, a single condition can be the starting point for building multiple test-and-learn audiences to identify prime prospects. For example, GLP-1 patients have diverse treatment journeys; some pay out-of-pocket due to lack of insurance coverage, others switch brands for cost savings, and some purchase directly through patient websites. Each of these scenarios represents a distinct audience that can be created using MARS data, enabling highly personalized activation strategies.
Data sourcing and quality
How does MARS source and curate consumer data relevant to health audiences?
Our audiences are survey-based, first-party data built from the MARS Consumer Health Study and Kantar’s trusted LifePoints Panel. We do not use medical claims, insurance data, or personal health records; our data is 100% self-reported. The study has over 5,000 different healthcare data points used to create syndicated and custom audiences. Our syndicated audiences are curated based on marketplace trends (e.g., we’ve added more information on GLP-1s), client feedback for enhancements to the MARS study, and reaching audiences medical claims data cannot (e.g., caregivers, treatment satisfaction, act based on healthcare advertising).
What data quality standards do you follow, and how do you ensure consistency and reliability, especially for sensitive or regulated health-related data?
M3 MI is part of M3 Global Research which is committed to transparency and high-quality data with ISO (International Organization for Standardization) certifications. These certifications demonstrate that our research practices align with international regulations.
In a crowded data marketplace, what unique attributes set MARS apart, particularly for health advertisers?
We don’t just identify patients or caregivers, we uncover their motivations, preferences, and behaviors, enabling advertisers to build highly targeted and meaningful audiences that competitors simply can’t replicate.
The MARS Consumer Health Study offers an extensive range of data for audience building, spanning healthy living profiles, OTC, vitamins, and prescription purchasing behaviors, as well as media consumption habits and lifestyle activities.
How MARS ensures regulatory compliance
What measures does MARS take to maintain data privacy and regulatory compliance?
We take a privacy-first approach to exceed all Network Advertising Initiative (NAI), Health Insurance Portability and Accountability Act (HIPAA), and California Consumer Privacy Act (CCPA) regulations. Since the data to build our audiences is self-reported via the MARS Consumer Health Study, we do not use PII data. We also take the following steps to maintain data privacy and compliance:
- State regulatory compliance: We proactively exclude survey respondents for audience seeds from certain states with consumer privacy laws that preclude audience data use
- Consent and transparency: Survey panelists are required to double-opt-in to all data usage terms before participating in the MARS study. Our panel partner’s privacy policy clearly explains use cases such as look-alike modeling and audience creation.
- Privacy-safe modeling: Data is scaled using propensity models built from an offline, people-based national consumer database. All seed survey data is removed from final models to eliminate any risk of re-identification, ensuring respondents are never targeted directly based on their survey responses.
Click here for full details on M3 MI’s privacy policy
How do these efforts help advertisers navigate an evolving regulatory landscape while ensuring ethical standards?
By relying solely on double opt-in, self-reported data, and removing identifiers, we guarantee that our approach is 100% privacy-safe and compliant. This gives advertisers confidence that our audiences are built on ethical, transparent practices without compromising consumer trust.
Success stories
Could you share a recent success story where a health advertiser achieved significant campaign improvements using M3 MI’s MARS data? What were the key factors behind that success, such as ROI, engagement lift, or conversion rates?
One recent success story involved a diabetes medical device advertiser trying to breakthrough in a cluttered marketing landscape. Their initial broad, non-personalized media campaign delivered lower than expected digital engagement. To address this, the company conducted segmentation research and identified three distinct patient personas. However, the research lacked actionable media insights and a way to effectively reach these personas in the digital world.
That’s where MARS data came in. Using the MARS Consumer Health Study, M3 MI mapped the existing personas to uncover each group’s unique media habits. These insights enabled the media agency to design tailored strategies for each persona. Additionally, M3 MI built custom, propensity-modeled persona audiences for activation across CTV, social, and display channels, ensuring precise targeting and personalized messaging. This strategic shift to personalized persona marketing transformed the campaign from a one-size-fits-all approach to a patient-first model. The company saw a significant lift in website engagement and a measurable increase in ROI.
Resources to maximize your campaigns
Where can readers find additional resources, case studies, or insights to learn more about MARS audience solutions?
Interested healthcare marketers can explore additional resources by visiting our Audience Solutions page. There, they’ll find a comprehensive overview, a detailed taxonomy of syndicated audiences, and other helpful materials. For personalized support or further information on customized audiences, they can also reach us directly at info@M3-MI.com.
Contact us
About our expert
Dan Lynch
Senior Manager, Insights and Analysis, M3 MI
Dan Lynch is a seasoned leader in strategic marketing insights and activation with over 20 years at healthcare focused media agencies. At M3 MI, he helps pharmaceutical companies, media partners, and agencies leverage our syndicated research to address critical business needs. Dan is also a lead of the MARS addressable audience initiative, applying his expertise in developing unique audience personas from our data and activating them across programmatic channels.
About M3 MI
M3 MI, a division of M3 USA, is the leading provider of unbiased syndicated research for the healthcare industry. We specialize in media measurement, advertising intelligence, and audience insights and activation. Leveraging robust datasets, rigorous methodologies, and decades of healthcare expertise, M3 MI delivers a deeper understanding of patients, caregivers, and healthcare professionals, their behaviors, attitudes, media habits, and communication preferences. These insights empower marketers to make informed, data-driven decisions.
Latest posts
Cross-Screen Pioneer Explores the Power of Connected Cars as a Vehicle for Customer Engagement LAS VEGAS, NV — (October 26, 2016) –Kate O’Loughlin, GM of Media for Tapad, addressed the J.D. Power Automotive conference audience today in Las Vegas, NV. With more than 1,400 participants representing every facet of the automotive marketing profession, the conference has become the industry's leading marketing event. Bringing the unified, cross-screen perspective to the stage, O’Loughlin discussed the vital role of connected cars in the consumer engagement process. She is a founding member of Tapad which launched the world’s first cross-screen marketing technology in 2010. Tapad was acquired by the Telenor Group early in 2016. Key points from O’Loughlin’s J.D. Power 2016 address included: The marketers who deliver relevant and engaging content in a privacy-safe setting will be in the strongest position to navigate the proliferation of connected devices, including the connected points in cars. As automakers innovate the technology in cars, marketers need to be prepared for the size and diversity of data available for understanding consumers. It’s going to be increasingly difficult to wade through the data, so now is the time to build a solid framework for understanding the person behind the data. Marketers who evolve — and take a holistic approach — to their campaign measurements will achieve marked improvements in efficiency and an enhanced understanding of their core audiences. Actionable brand engagement metrics like Viewable Exposure Time (VET) will continue to overtake traditional advertising performance metrics. VET evaluates the optimal amount of time an ad is present on a screen to incite consumer action. In early testing by Tapad, campaigns that employ VET see conversion rate performance improvements from 13 to 60%. The consumer-centric technology solutions of the future need to be as scalable as they are affordable. Learn more about Tapads’ recommended Viewable Exposure Time metric contact us today! Contact us today
NEW YORK, Sept. 28, 2016 /PRNewswire/ – Tapad, the leader in cross-device marketing technology, today announced a new metric for cross-device marketers, Viewable Exposure Time (VET). Viewable Exposure Time measures across screens and ad formats, identifying the optimal amount of time a consumer spends with an ad before they take action. The announcement coincides with Unify Tech '16, Tapad's third-annual cross-device summit during Advertising Week NY. Frequency caps are currently used to ensure that dollars aren't wasted on redundant ads. Viewable Exposure Time evolves the frequency capping approach to include accelerating a consumer's ad exposure rate up to the optimal time spent with the brand. VET is used in affinity, digital transaction and offline purchase models as a key indicator of marketing budget well-spent. Beta users of VET span every vertical, though interest is especially high from CPG, Automotive, Telecommunications and Retail. Viewable Exposure Time unifies and upgrades marketers' predictors of advertising success by leveraging cross-screen engagement across digital and television, with vendor-agnostic viewability scores for video, rich media and display. "Today's current measurement options, like click-through rate (CTR) and TV gross ratings points (GRP) tell an incomplete story," said Tapad GM of Media Kate O'Loughlin. "Tapad is focused on measuring what really matters to marketers – building an efficient connection with a customer. Innovation in metrics was long overdue." More than just a measurement tool, Tapad also provides clients with VET activation. Factoring in time spent with ads in viewable seconds and minutes, these analytics inform marketers about which audiences are underexposed, enabling them to adjust campaigns and deliver according to optimal viewable exposure time. This effectively increases conversion rates at the lowest cost. Contact us today
Strong Revenue Performance and Thriving Culture Contribute to Industry Recognition NEW YORK, Sept. 15, 2016 /PRNewswire/ — Tapad, the leader in cross-device marketing technology and now a part of Experian, was named a top company on Inc. Magazine’s list of the 5000 fastest-growing private companies in the U.S. In addition, Tapad won the TMCnet 2016 Tech Culture Award. The exclusive Inc. 5000 ranking highlights the fastest-growing privately-held* companies in America. These distinguished companies have achieved success in strategy, service and innovation. TMCnet recognizes talented tech professionals who are committed to building a culture that prioritizes employee growth, collaboration and engagement. Tapad continues to broaden their presence into new markets, having launched in APAC earlier this year, as well as continuing their European expansion. Tapad’s proprietary technology, The Device Graph™ is leveraged by more marketers and brands to understand digital engagement across devices. The company’s rapidly expanding client base includes numerous Fortune 500 company brands as well as all four major advertising holding companies in the U.S. “We have an exceptional team of innovative people who are all working very hard to achieve the kind of results these publications are recognizing,” said Tapad CEO and Founder, Are Traasdahl. “Given that, we have an even greater responsibility to our talent to create an environment that fosters innovation and nurtures open communication. Ultimately, this is how we will continue to reach our very ambitious goals of becoming the world’s leading unified marketing technology provider.” Tapad’s award-winning work culture is defined by its gold-standard benefits which include a six-month parental leave policy, unlimited vacation time, company-sponsored meals and office space designed to facilitate collaboration and open communication. Tapad’s highly talented team has also received multiple customer service awards in 2016. These awards include the iMedia ASPY awards for Best Customer Service and Best Mobile Partner as well as recognition from The Communicator Awards of Excellence in Interactive Media. *Prior to Tapad’s acquisition by Telenor in February 2016. Contact us today